RVMD - Revolution Medicines, Inc.

QQQ $ 611.70 $ 5.09 (0.84 %)

DIA $ 467.20 $ 1.51 (0.32 %)

SPY $ 672.21 $ 3.96 (0.59 %)

TLT $ 91.38 $ -0.63 (-0.68 %)

GLD $ 378.90 $ 1.51 (0.4 %)

Previous Close

$ 53.44

Open

$ 53.15

Bid

$ 52.50 x 1

Ask

$ 54.00 x 21

Day's Range

$ 52.48 - $ 54.08

52 Week Range

$ 29.17 - $ 62.40

Volume

1,867,589

Average Volume

Market Cap

9.99B

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-07-2025	03-31-2025	10-Q
3	02-26-2025	01-01-1970	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-26-2024	12-31-2023	10-K
8	11-06-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	02-27-2023	12-31-2022	10-K
12	11-07-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-11-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	03-02-2021	12-31-2020	10-K
20	11-12-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-14-2020	03-31-2020	10-Q
23	03-30-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

tango-therapeutics-touts-encouraging-data-from-early-stage-cancer-trial-raises-capital-to-fund-advancement

Tango Therapeutics Touts Encouraging Data ...
10/23/2025 15:17:16

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with ...

Revolution Medicines Reports 42% Objective...
10/22/2025 16:16:24

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients wit...

Mizuho Initiates Coverage On Revolution Me...
10/21/2025 12:47:09

Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and announ...

Raymond James Maintains Strong Buy on Revo...
10/17/2025 16:34:01

Raymond James analyst Sean McCutcheon maintains Revolution Medicines (NASDAQ:RVMD) with a Strong Buy and raises the price ta...

revolution-medicines-disc-medicine-american-express-and-other-big-stocks-moving-higher-on-friday

Revolution Medicines, Disc Medicine, Ameri...
10/17/2025 16:02:18

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

Wedbush Reiterates Outperform on Revolutio...
10/17/2025 12:26:34

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $77 price target.

no-need-to-sell-martin-marietta-materials-cramer-says-its-just-a-great-long-term-hold

'No Need To Sell' Martin Marietta Material...
10/17/2025 11:46:17

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a pri...

FDA Awards First-Ever National Priority Vo...
10/16/2025 21:27:26

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

Stifel Reinstates Buy on Revolution Medici...
10/16/2025 13:46:45

Stifel analyst Laura Prendergast reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $85 price target.

Goldman Sachs Maintains Buy on Revolution ...
09/12/2025 17:07:29

Goldman Sachs analyst Andrea Newkirk maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target fro...

Raymond James Assumes Revolution Medicines...
09/12/2025 12:13:02

Raymond James analyst Sean McCutcheon assumes Revolution Medicines (NASDAQ:RVMD) with a Strong Buy rating and announces Pric...

analysts-raise-price-targets-following-strong-data-from-revolution-medicines-pancreatic-cancer-drug

Analysts Raise Price Targets Following Str...
09/11/2025 18:14:44

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response ra...

Wedbush Maintains Outperform on Revolution...
09/11/2025 12:41:37

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

Wells Fargo Maintains Overweight on Revolu...
09/11/2025 12:40:18

Wells Fargo analyst Eva Fortea Verdejo maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price t...

12 Health Care Stocks Moving In Thursday's...
09/11/2025 12:10:10

aon-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday

Aon To Rally Around 19%? Here Are 10 Top A...
09/11/2025 12:08:16

Needham Maintains Buy on Revolution Medici...
09/11/2025 11:11:35

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $56 to $66.

12 Health Care Stocks Moving In Wednesday'...
09/10/2025 21:06:05

Revolution Medicines Reports Daraxonrasib ...
09/10/2025 20:24:40

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces pro...